NCT06880679 Ultrasound Acute Chest Syndrome Sickle Cell Disease
| NCT ID | NCT06880679 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Acute Chest Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-04-08 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-04-08 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Feasibility and reliability of ultrasound in the inpatient hematology setting.
Eligibility Criteria
Inclusion Criteria: 1. Age: 0-25 years old 2. Diagnosis: Patients with a documented diagnosis of sickle cell disease (any genotype) 3. Disposition: Hospitalized for a SCD-related complication (e.g. VOC) Exclusion Criteria: 1. Patient is considered hemodynamically unstable to undergo consent and study procedures 2. Already has diagnosis of ACS prior to admission to inpatient unit 3. POCUS operator not available
Contact & Investigator
Seethal Jacob, MD
PRINCIPAL INVESTIGATOR
Indiana University
Frequently Asked Questions
Who can join the NCT06880679 clinical trial?
This trial is open to participants of all sexes, up to 25 Years, studying Acute Chest Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06880679 currently recruiting?
Yes, NCT06880679 is actively recruiting participants. Contact the research team at tcfisher@iu.edu for enrollment information.
Where is the NCT06880679 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT06880679 clinical trial?
NCT06880679 is sponsored by Indiana University. The principal investigator is Seethal Jacob, MD at Indiana University. The trial plans to enroll 30 participants.